Rx00001 - 4-Aminosalicylic Acid


Name:
4-Aminosalicylic Acid
Rx ID:
Rx00001
Validation Level:
Phenomic Similarity:
0.511
Reference ID:
DB00233
Primary Indications:
Tuberculosis
Orphan Indications:
No annotated orphan indications.
Rare Indications:
Ulcerative colitis; acute flares; pediatric Crohn's disease; Crohn's disease
Common Indications:
No annotated common indications.
Pathways:
Integrated Pancreatic Cancer Pathway; Serotonergic synapse - Homo sapiens (human); Retrograde endocannabinoid signaling - Homo sapiens (human); Disease; Leishmaniasis - Homo sapiens (human); Selenium ...Click to show more
Drug Interactions:
Azathioprine; Mercaptopurine; Sulindac; Tiaprofenic acid; Tioguanine; Tolmetin; Trandolapril; Treprostinil; Warfarin; ...
Click to show more...
Food Interactions:
Take without regard to meals.

Interactive 3D Model

Interactive Drug Target Network

Interactive Bipartite Drug Repurposing Graph

Rx00001
Primary Indication
Secondary Indication

Visualize Chemical Properties

Select x-axis

Select y-axis

Disease prevalence from Electronic Health Records

Click row to show all

Disease A Disease B A∩B A∩¬B B∩¬A Odds-Ratio P-Value Adjusted P-Value
tuberculosis pediatric Crohn's disease 27 1835 11834 5.017 3.31E-11 1.06e-07

Shared Genetic Architectures of Disease Pairs

Click row to show all

Disease A Disease B Adjusted P-Value Shared Gene IDs
TUBERCULOSIS ULCERATIVE COLITIS 1.62e-56 ABCB1, ACE, BTNL2, CARD8, CCL2, CCL3, CCL5, CCR5, CD14, CD209, CTLA4, CXCL12, CXCR1, CXCR2, CYBA, CYP2A6, CYP2D6, CYP3A4, CYP3A5, DEFB1, F5, FCGR2A, FCGR3A, GSTM1, GSTP1, GSTT1, HLA-A, HLA-B, HLA-C, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB4, HP, HSPA1L, IFITM3, IFNG, IL10, IL10RA, IL12B, IL13, IL17A, IL17F, IL18, IL1A, IL1B, IL1R1, IL1RN, IL2, IL22, IL23R, IL27, IL4, IL4R, IL6, IL8, IRGM, JAK2, KIR2DL2, KIR2DL3, KRAS, LTA, MBL2, MIF, MIR146A, MIR196A2, MIR499, MMP1, MMP12, MMP3, MMP9, MTHFR, MTRR, MYD88, NAT2, NCF4, NFKBIL1, NLRP3, NOD2, NOS2, NOS3, NQO1, NR1H2, NR1I2, PADI4, PPARG, PTGS2, PTPN22, SERPINA1, SFTPD, SLC11A1, SLC22A4, SLC22A5, SOD2, SPP1, STAT3, STAT4, TF, TGFB1, TLR1, TLR2, TLR4, TLR6, TLR9, TNF, TNFRSF1A, TNFRSF1B, TP53, TRNS1, VDR, ZNF365

Chemical, Pharmacological and Biological Annotations


ATC Code:
J04AA01
Brands:
Pamisyl (Parke-Davis); Rexipas (Bristol-Myers Squibb); Rezipas (Bristol-Myers Squibb)
Category:
Antitubercular Agents
ChEBI ID:
27565
PubChem ID:
4649
KEGG Drug ID:
D00162
SMILE:
NC1=CC(O)=C(C=C1)C(O)=O
InChI:
1S/C7H7NO3/c8-4-1-2-5(7(10)11)6(9)3-4/h1-3,9H,8H2,(H,10,11)
Classification:
Kingdom:
Organic Compounds
Superclass:
Benzenoids
Class:
Benzene and Substituted Derivatives
Subclass:
Benzoic Acid and Derivatives
Indication:
For the treatment of tuberculosis
Pharmacodynamics:
Aminosalicylic acid is an anti-mycobacterial agent used with other anti-tuberculosis drugs (most often isoniazid) for the treatment of all forms of active tuberculosis due to susceptible strains of tubercle bacilli. The two major considerat...
Click to show more...
Description:
An antitubercular agent often administered in association with isoniazid. The sodium salt of the drug is better tolerated than the free acid. [PubChem]
Mechanism:
There are two mechanisms responsible for aminosalicylic acid's bacteriostatic action against <i>Mycobacterium tuberculosis</i>. Firstly, aminosalicylic acid inhibits folic acid synthesis (without potentiation with antifolic compounds). The ...
Click to show more...

Adsorption, Distribution, Metabolism, Excretion and Toxicity


Human Intestinal Absorption:
+
Blood Brain Barrier:
-
Caco-2 permeable:
-
P-glycoprotein substrate:
Non-substrate
P-glycoprotein inhibitor I:
Non-inhibitor
P-glycoprotein inhibitor II:
Non-inhibitor
Renal organic cation transporter:
Non-inhibitor
CYP450 2C9 substrate:
Non-inhibitor
CYP450 2D6 substrate:
Non-inhibitor
CYP450 2C19 substrate:
Inhibitor
CYP450 inhibitory promiscuity:
Low CYP Inhibitory Promiscuity
Ames test:
Non AMES toxic
Carcinogenicity:
Non-carcinogens
Biodegradation:
Ready biodegradable
Rat acute toxicity:
1.5761 LD50, mol/kg
hERG inhibition (predictor I):
Weak inhibitor
hERG inhibition (predictor II):
Non-inhibitor

Contact Us:
Please contact us if you have questions or comments about RepurposeDB. You can also contact us if you need help in submitting your drug repositioning investigation to RepurposeDB.


Dudley Laboratory
Department of Genetics and Genomic Sciences
Icahn Institute for Genomics and Multiscale Biology
Icahn School of Medicine at Mount Sinai
One Gustave L. Levy Place, Box 1498
Manhattan, New York City, NY
repurposedb@dudleylab.org